Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRSN Stock Forecast 2026-2027
$29.08
Current Price
$145.36M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MRSN Price Targets
+5.7%
To High Target of $30.75
+5.7%
To Median Target of $30.75
+5.7%
To Low Target of $30.75
MRSN Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+227.5%
1 Year Change
+0.5%
Year-to-Date Change
-19.8%
From 52W High of $36.25
+458.2%
From 52W Low of $5.21
📊 TOP ANALYST CALLS
Did MRSN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mersana Therapeutics is one of their latest high-conviction picks.
Latest MRSN Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, MRSN has a neutral consensus with a median price target of $30.75 (ranging from $30.75 to $30.75). The overall analyst rating is Buy (6.0/10). Currently trading at $29.08, the median forecast implies a 5.7% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Asthika Goonewardene at Truist Securities, projecting a 5.7% upside. Conversely, the most conservative target is provided by Asthika Goonewardene at Truist Securities, suggesting a 5.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRSN Analyst Ratings
0
Buy
2
Hold
0
Sell
MRSN Price Target Range
Low
$30.75
Average
$30.75
High
$30.75
Current: $29.08
Latest MRSN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRSN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Guggenheim | Michael Schmitz | Neutral | Downgrade | $N/A |
| Nov 13, 2025 | BTIG | Justin Zelin | Neutral | Downgrade | $N/A |
| Nov 13, 2025 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $30.75 |
| Aug 14, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $36.00 |
| Aug 14, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $30.00 |
| May 16, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $5.00 |
| May 16, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $10.00 |
| Feb 6, 2025 | William Blair | Andy Hsieh | Outperform | Initiates | $N/A |
| Aug 27, 2024 | Citigroup | Ashiq Mubarack | Buy | Maintains | $5.00 |
| Aug 14, 2024 | Baird | Colleen Kusy | Neutral | Maintains | $3.00 |
| Mar 19, 2024 | JP Morgan | Brian Cheng | Neutral | Upgrade | $5.00 |
| Feb 29, 2024 | Guggenheim | Michael Schmidt | Buy | Upgrade | $7.00 |
| Feb 29, 2024 | Baird | Colleen Kusy | Neutral | Maintains | $5.00 |
| Feb 29, 2024 | Wedbush | David Nierengarten | Outperform | Upgrade | $7.00 |
| Feb 29, 2024 | Truist Securities | Asthika Goonewardene | Buy | Upgrade | $9.00 |
| Dec 4, 2023 | Citigroup | Ashiq Mubarack | Buy | Upgrade | $5.00 |
| Aug 8, 2023 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2023 | Credit Suisse | Outperform | Reiterates | $N/A | |
| Aug 7, 2023 | Needham | Buy | Reiterates | $N/A |
Mersana Therapeutics, Inc. (MRSN) Competitors
The following stocks are similar to Mersana Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mersana Therapeutics, Inc. (MRSN) Financial Data
Mersana Therapeutics, Inc. has a market capitalization of $145.36M with a P/E ratio of -2.1x. The company generates $33.18M in trailing twelve-month revenue with a -211.2% profit margin.
Revenue growth is -12.6% quarter-over-quarter, while maintaining an operating margin of -67.9% and return on equity of +727.6%.
Valuation Metrics
Market Cap
$145.36M
Enterprise Value
$91.27M
P/E Ratio
-2.1x
PEG Ratio
0.1x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
-12.6%
Gross Margin
N/A
Operating Margin
-67.9%
Net Margin
-211.2%
EPS Growth
-12.6%
Financial Health
Cash/Price Ratio
+38.8%
Current Ratio
1.4x
Debt/Equity
0.0x
ROE
+727.6%
ROA
-36.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mersana Therapeutics, Inc. (MRSN) Business Model
About Mersana Therapeutics, Inc.
What They Do
Develops novel antibody-drug conjugates for cancer.
Business Model
Mersana Therapeutics operates as a clinical-stage biopharmaceutical company focused on creating and advancing antibody-drug conjugates (ADCs). The company generates revenue through collaborations with major biopharmaceutical companies, which support its research and development of ADCs aimed at improving cancer treatment outcomes.
Additional Information
Mersana's proprietary technology platforms, Dolasynthen and Immunosynthen, allow for the development of ADCs with new cytotoxic and immunostimulatory payloads, enhancing their efficacy and tolerability. The company's key candidates include Emi-Le (XMT-1660) and XMT-2056, both currently in Phase 1 clinical trials, indicating potential future growth in the oncology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
102
CEO
Dr. Martin H. Huber M.D.
Country
United States
IPO Year
2017
Website
www.mersana.comMersana Therapeutics, Inc. (MRSN) Latest News & Analysis
Latest News
Quick Summary
The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for potential breaches of fiduciary duty related to its transaction with Day One Biopharmaceuticals.
Why It Matters
The investigation into Mersana for potential fiduciary breaches could impact its stock price and investor confidence, signaling risks associated with corporate governance and legal compliance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. announced developments in New York and New Orleans on December 12, 2025, which may impact regional legal and business environments.
Why It Matters
The mention of a former Attorney General in a news release may signal potential legal developments or regulatory changes that could affect market conditions or specific sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Mersana Therapeutics shares surged after Day One Biopharmaceuticals announced an acquisition deal valued at up to $285 million.
Why It Matters
The acquisition of Mersana Therapeutics by Day One Biopharmaceuticals for up to $285 million suggests strong market confidence and potential value growth, impacting investor sentiment positively.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Mersana Therapeutics will be acquired by Day One Biopharmaceuticals. An M&A call is scheduled for November 13, 2025, featuring key executives and analysts from major financial firms.
Why It Matters
Mersana Therapeutics' acquisition by Day One Biopharmaceuticals indicates potential growth and strategic alignment, affecting stock valuations and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
An agreement with Day One Biopharmaceuticals offers $25.00 per share upfront and potential cash payments up to $30.25 per share, totaling approximately $285 million.
Why It Matters
The agreement signals potential revenue growth for the acquiring company, enhancing shareholder value with significant upfront and contingent payments linked to future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for potential fiduciary duty breaches related to its transaction with Day One Biopharmaceuticals.
Why It Matters
Potential legal issues surrounding Mersana's transaction may impact its stock value, investor confidence, and future profitability, prompting scrutiny from shareholders.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MRSN Stock
What is Mersana Therapeutics, Inc.'s (MRSN) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Mersana Therapeutics, Inc. (MRSN) has a median price target of $30.75. The highest price target is $30.75 and the lowest is $30.75.
Is MRSN stock a good investment in 2026?
According to current analyst ratings, MRSN has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRSN stock?
Wall Street analysts predict MRSN stock could reach $30.75 in the next 12 months. This represents a 5.7% increase from the current price of $29.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mersana Therapeutics, Inc.'s business model?
Mersana Therapeutics operates as a clinical-stage biopharmaceutical company focused on creating and advancing antibody-drug conjugates (ADCs). The company generates revenue through collaborations with major biopharmaceutical companies, which support its research and development of ADCs aimed at improving cancer treatment outcomes.
What is the highest forecasted price for MRSN Mersana Therapeutics, Inc.?
The highest price target for MRSN is $30.75 from Asthika Goonewardene at Truist Securities, which represents a 5.7% increase from the current price of $29.08.
What is the lowest forecasted price for MRSN Mersana Therapeutics, Inc.?
The lowest price target for MRSN is $30.75 from Asthika Goonewardene at Truist Securities, which represents a 5.7% increase from the current price of $29.08.
What is the overall MRSN consensus from analysts for Mersana Therapeutics, Inc.?
The overall analyst consensus for MRSN is neutral. Out of 13 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $30.75.
How accurate are MRSN stock price projections?
Stock price projections, including those for Mersana Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 6:28 PM UTC